{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T06:55:28Z","timestamp":1781765728458,"version":"3.54.5"},"reference-count":32,"publisher":"Elsevier BV","issue":"40","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.vaccine.2020.07.039","type":"journal-article","created":{"date-parts":[[2020,7,31]],"date-time":"2020-07-31T17:33:46Z","timestamp":1596216826000},"page":"6291-6298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra\u00ae) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005\u20132016"],"prefix":"10.1016","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3213-8402","authenticated-orcid":false,"given":"Tanya R.","family":"Myers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"McNeil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen S.","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paige L.","family":"Marquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro L.","family":"Moro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saad B.","family":"Omer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria V.","family":"Cano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.07.039_b0005","unstructured":"Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 2005; 54 (RR-7):1\u201321."},{"key":"10.1016\/j.vaccine.2020.07.039_b0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/01.inf.0000148928.10057.86","article-title":"Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year old children","volume":"24","author":"Pichichero","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.07.039_b0015","first-page":"1391","article-title":"Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease","volume":"60","author":"Centers for Disease Control and Prevention.","year":"2011","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2020.07.039_b0020","unstructured":"Food and Drug Administration. Package insert -- Menactra\u00ae. Rockville, MD: US Department of Health and Human Services, Food and Drug Administration, Center for Biologics Evaluation and Research; 2018. Available at https:\/\/www.fda.gov\/media\/75619\/download (accessed December 2, 2019)."},{"key":"10.1016\/j.vaccine.2020.07.039_b0025","unstructured":"Centers for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62(RR-2):1\u201328."},{"key":"10.1016\/j.vaccine.2020.07.039_b0030","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.15585\/mmwr.mm6543a3","article-title":"Recommendations for use of meningococcal conjugate vaccines in HIV-infected persons - Advisory Committee on Immunization Practices, 2016","volume":"65","author":"Centers for Disease Control and Prevention.","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2020.07.039_b0035","unstructured":"Centers for Disease Control and Prevention. Guillain-Barr\u00e9 syndrome among recipients of Menactra\u00ae meningococcal conjugate vaccine \u2013 United States, June 2005-July 2005. MMWR Morb Mortal Wkly Rep 2005; 54(Dispatch):1\u20133."},{"key":"10.1016\/j.vaccine.2020.07.039_b0040","first-page":"364","article-title":"Update: Guillain-Barr\u00e9 syndrome among recipients of Menactra\u00ae meningococcal conjugate vaccine \u2013 United States, October 2005-February 2006","volume":"55","author":"Centers for Disease Control and Prevention.","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2020.07.039_b0045","first-page":"1120","article-title":"Update: Guillain-Barr\u00e9 syndrome among recipients of Menactra\u00ae meningococcal conjugate vaccine \u2013 United States, June 2005-September 2006","volume":"55","author":"Centers for Disease Control and Prevention.","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2020.07.039_b0050","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/pds.3321","article-title":"Risk of Guillain-Barr\u00e9 syndrome after meningococcal conjugate vaccination","volume":"21","author":"Velentgas","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2020.07.039_b0055","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1002\/pds.3353","article-title":"No risk of Guillain-Barr\u00e9 syndrome found after meningococcal conjugate vaccination in two large cohort studies","volume":"21","author":"Yih","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2020.07.039_b0060","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1016\/j.vaccine.2018.02.107","article-title":"Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children","volume":"36","author":"Hansen","year":"2018","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.039_b0065","doi-asserted-by":"crossref","first-page":"6879","DOI":"10.1016\/j.vaccine.2017.09.032","article-title":"Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine","volume":"35","author":"Hansen","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.039_b0070","doi-asserted-by":"crossref","first-page":"4912","DOI":"10.1016\/j.vaccine.2009.06.038","article-title":"Risk of medically attended local reactions following diphtheria toxoid containing vaccines in adolescents and young adults: a Vaccine Safety Datalink study","volume":"27","author":"Jackson","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.039_b0075","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/pds.4397","article-title":"Meningococcal conjugate vaccine safety surveillance in the Vaccine Safety Datalink using a tree-temporal scan data mining method","volume":"27","author":"Li","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.vaccine.2020.07.039_b0080","doi-asserted-by":"crossref","first-page":"874","DOI":"10.15585\/mmwr.mm6633a2","article-title":"National, regional, state, and selected local area vaccination coverage among adolescents aged 13\u201317 years \u2013 United States, 2016","volume":"66","author":"Centers for Disease Control and Prevention.","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.vaccine.2020.07.039_b0085","doi-asserted-by":"crossref","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.039_b0090","unstructured":"U.S. Code of Federal Regulations, 21 CFR 600.80. Postmarketing reporting of adverse experiences; 2014. Available at: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=600.80 [accessed 10.8.2019]."},{"key":"10.1016\/j.vaccine.2020.07.039_b0095","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1016\/j.vaccine.2007.02.064","article-title":"Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data","volume":"25","author":"R\u00fcggeberg","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.039_b0100","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1016\/j.vaccine.2016.05.023","article-title":"Facial nerve palsy including Bell\u2019s palsy: Case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"35","author":"Rath","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.039_b0105","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.vaccine.2010.06.003","article-title":"Guillain-Barr\u00e9 syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data","volume":"29","author":"Sejvar","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.039_b0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"key":"10.1016\/j.vaccine.2020.07.039_b0115","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.vaccine.2020.07.039_b0120","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1111\/bcp.13736","article-title":"Safety of bivalent human papillomavirus vaccine in the US Vaccine Adverse Event Reporting System (VAERS), 2009\u20132017","volume":"84","author":"Suragh","year":"2018","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.vaccine.2020.07.039_b0125","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/j.vaccine.2018.02.034","article-title":"Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS)","volume":"36","author":"Arana","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.039_b0130","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.vaccine.2012.10.097","article-title":"postlicensure safety surveillance for adolescent and adult tetanus, diphtheria and acellular pertussis vaccines: 2005\u20132007","volume":"31","author":"Chang","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.07.039_b0135","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.vaccine.2017.02.030","article-title":"Adverse events following quadrivalent meningococcal CRM-conjugate vaccine (Menveo\u00ae) reported to the Vaccine Adverse Event Reporting System (VAERS), 2010\u20132015","volume":"35","author":"Myers","year":"2017","journal-title":"Vaccine"},{"issue":"478","key":"10.1016\/j.vaccine.2020.07.039_b0140","first-page":"e1","article-title":"Safety of meningococcal polysaccharide-protein conjugate vaccine in pregnancy: a review of the Vaccine Adverse Event Reporting System","volume":"208","author":"Zheteyeva","year":"2013","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.vaccine.2020.07.039_b0145","unstructured":"Ezeanolue E, Harriman K, Hunter P, Kroger A, Pellegrini C. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). [www.cdc.gov\/vaccines\/hcp\/acip-recs\/generalrecs\/downloads\/general-recs.pdf]. Accessed on 12.10.2019."},{"key":"10.1016\/j.vaccine.2020.07.039_b0150","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1080\/21645515.2018.1445447","article-title":"Meningococcal vaccination in pregnancy","volume":"14","author":"Raya","year":"2018","journal-title":"Human Vaccines & Immunother"},{"key":"10.1016\/j.vaccine.2020.07.039_b0155","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1093\/cid\/ciw607","article-title":"Acute demyelinating events following vaccines: a case-centered analysis","volume":"63","author":"Baxter","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2020.07.039_b0160","doi-asserted-by":"crossref","first-page":"S737","DOI":"10.1093\/ofid\/ofy210.2114","article-title":"Safety of quadrivalent meningococcal polysaccharide diptheria toxoid-conjugate vaccine in adolescents","volume":"5","author":"Myers","year":"2018","journal-title":"Open Forum Infect. Dis."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20309579?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20309579?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:47:15Z","timestamp":1759402035000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20309579"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":32,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["S0264410X20309579"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.039","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Adverse events following quadrivalent meningococcal diphtheria toxoid conjugate vaccine (Menactra\u00ae) reported to the Vaccine Adverse Event Reporting System (VAERS), 2005\u20132016","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.07.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}